June 29, 2020 / 9:08 AM / 7 days ago

BRIEF-Roche’s Enspryng Approved In Japan For Patients With Neuromyelitis Optica Spectrum Disorder

June 29 (Reuters) - Roche Holding AG:

* ROCHE’S ENSPRYNG®️ (SATRALIZUMAB) APPROVED IN JAPAN FOR ADULTS AND CHILDREN WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER

* ENSPRYNG IS JAPAN’S FIRST AND ONLY APPROVED THERAPY FOR BOTH ADULTS AND CHILDREN WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)

* ENSPRYNG IS FIRST AND ONLY APPROVED THERAPY TARGETING INTERLEUKIN-6 (IL-6) RECEPTOR GIVEN SUBCUTANEOUSLY EVERY FOUR WEEKS

* APPROVAL IS SUPPORTED BY DATA DEMONSTRATING ENSPRYNG’S ROBUST EFFICACY, WHICH WAS WELL-TOLERATED WITH A CONSISTENT SAFETY PROFILE, IN A BROAD NMOSD POPULATION AS A MONOTHERAPY AND AS AN ADD-ON THERAPY

* ASIA HAS A HIGH PREVALENCE OF NMOSD WITH LIMITED TREATMENT OPTIONS Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below